SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-19-325415
Filing Date
2019-12-30
Accepted
2019-12-30 08:10:34
Documents
6
Period of Report
2019-12-22
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 5.01: Changes in Control of Registrant
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d813704d8k.htm 8-K 35328
2 EX-10.1 d813704dex101.htm EX-10.1 197000
3 EX-10.2 d813704dex102.htm EX-10.2 215526
4 EX-99.1 d813704dex991.htm EX-99.1 14667
5 EX-99.2 d813704dex992.htm EX-99.2 11352
6 GRAPHIC g813704g1228023106995.jpg GRAPHIC 3381
  Complete submission text file 0001193125-19-325415.txt   480220
Mailing Address 5281 CALIFORNIA AVENUE SUITE 100 IRVINE CA 92617
Business Address 5281 CALIFORNIA AVENUE SUITE 100 IRVINE CA 92617 949-226-6029
Urovant Sciences Ltd. (Filer) CIK: 0001740547 (see all company filings)

IRS No.: 000000000 | State of Incorp.: D0 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-38667 | Film No.: 191314822
SIC: 2834 Pharmaceutical Preparations